middle.news

Clarity Clears Final Follow-Up Hurdle Before 2027 Prostate Cancer Readout

8:33am on Thursday 19th of November, 2026 AEDT • Biotechnology and Pharmaceuticals
Read Story

Clarity Clears Final Follow-Up Hurdle Before 2027 Prostate Cancer Readout

8:33am on Thursday 19th of November, 2026 AEDT
Key Points
  • Final follow-up assessments completed for all AMPLIFY participants
  • Phase III trial targets recurrent prostate cancer after initial treatment
  • Coprimary endpoints cover correct detection rate and positive predictive value
  • Topline AMPLIFY and CLARIFY data expected in the first half of 2027
Read Story
middle.

Tap to Read

Tap the card to read the full analysis
about Clarity Pharmaceuticals (ASX:CU6)
OPEN ARTICLE